Already billed as a potential blockbuster, Amgen and AstraZeneca’s Tezspire has turned in strong clinical data in chronic ...

Four years after Sanofi shelled out $125 million for global rights to Biond Biologic | The company is handing back the tumor ...

Kuehne+Nagel supports Sanofi in multiple countries worldwide, including Hungary, the UK, and the UAE, by providing customised ...

Immunology is a rapidly advancing field with significant potential for growth, especially in the realm of biotech and pharmaceutical companies.

Pursuant to Regulation 24 (A) if the SEBI (listing obligations and disclosure requirement ) Regulations, 2015, please find enclosed annual secretarial compliance report for the year ended December ...

Novavax said it was eligible to receive royalties in high teens to low twenties percent on Sanofi sales, up to $350 million ...

Subject to shareholder approval at the subsequent Annual General Meeting (AGM), the Board of Directors of Sanofi Consumer ...

Zacks Research cut their Q2 2025 EPS estimates for shares of Sanofi in a research report issued on Wednesday, February 19th.

In this article, we are going to take a look at where Sanofi (NASDAQ:SNY) stands against the other pharmaceutical stocks.

Sanofi Consumer Healthcare India Limited ( ($IN:SANOFICONR) ) just unveiled an update. Sanofi Consumer Healthcare India ...

The pharma signed an agreement handing PE firm CD&R a 50% stake in its Capella unit. Elsewhere, Gilead and Ultragenyx secured ...

Sanofi and CD&R have signed a share purchase agreement for the sale of a 50% stake in the consumer health business.